Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.64 |
| ▸ | ALDH1A2 | O94788 | 2/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.58 |
| ▸ | HTR3A | P46098 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL424973 | 1.00 | HRH3 (0.64) | HRH3ALDH1A2KCNH2HTR3AMAOA | |
| SCHEMBL428304 | 0.81 | MAOA (0.80) | HRH3MAOAMAOB | |
| SCHEMBL23097695 | 0.80 | KCNH2 (0.56) | KCNH2MAOAMAOB | |
| SCHEMBL24508392 | 0.79 | ALDH1A2 (0.73) | ALDH1A2MAOAMAOB | |
| SCHEMBL24509416 | 0.78 | ALDH1A2 (0.81) | ALDH1A2MAOAMAOB | |
| SCHEMBL1373601 | 0.78 | HRH3 (0.67) | HRH3KCNH2HTR3A | |
| SCHEMBL1373596 | 0.78 | HRH3 (0.67) | HRH3KCNH2HTR3A | |
| SCHEMBL24508861 | 0.78 | ALDH1A2 (0.69) | ALDH1A2MAOAMAOB | |
| SCHEMBL1375303 | 0.78 | HRH3 (1.00) | HRH3KCNH2HTR3A | |
| SCHEMBL1375310 | 0.78 | HRH3 (1.00) | HRH3KCNH2HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609847-B2 | Dihydroquinolinone derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2013-12-17 | — | — | US | disclosed |
| EP-2393802-B1 | DIHYDROQUINOLINONE DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2013-05-08 | — | — | EP | disclosed |
| US-20120022064-A1 | DIHYDROQUINOLINONE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| EP-2393802-A1 | DIHYDROQUINOLINONE DERIVATIVES | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010090347-A1 | DIHYDROQUINOLINONE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022064-A1 | DIHYDROQUINOLINONE DERIVATIVES | PER2, CRY1, BACE1 | HRH3 29/4885ALDH1A2 148/4885KCNH2 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.